These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9159401)

  • 1. Antibiotic-induced endotoxin release from bacteria and its clinical significance.
    Kirikae T; Nakano M; Morrison DC
    Microbiol Immunol; 1997; 41(4):285-94. PubMed ID: 9159401
    [No Abstract]   [Full Text] [Related]  

  • 2. Release of endotoxin from bacteria exposed to ciprofloxacin and its prevention with polymyxin B.
    Cohen J; McConnell JS
    Eur J Clin Microbiol; 1986 Feb; 5(1):13-7. PubMed ID: 3009177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic-induced release of endotoxin: a reappraisal.
    Hurley JC
    Clin Infect Dis; 1992 Nov; 15(5):840-54. PubMed ID: 1445982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study.
    Dofferhoff AS; Nijland JH; de Vries-Hospers HG; Mulder PO; Weits J; Bom VJ
    Scand J Infect Dis; 1991; 23(6):745-54. PubMed ID: 1815338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic-induced bacterial cell lysis: a therapeutic dilemma.
    Shenep JL
    Eur J Clin Microbiol; 1986 Feb; 5(1):11-2. PubMed ID: 2938943
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymyxin-B endotoxin removal device: making the point on mechanisms of action, clinical effectiveness and possible future applications: review.
    Ruberto F; Ianni S; Babetto C; Magnanimi E; Ferretti G; Novelli G; Pugliese F
    Infect Disord Drug Targets; 2013 Apr; 13(2):128-32. PubMed ID: 23919356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.
    Yuan Z; Tam VH
    Expert Opin Investig Drugs; 2008 May; 17(5):661-8. PubMed ID: 18447592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin derivatives: a patent evaluation (WO2012168820).
    Wu H; Teng P; Niu Y; Li Q; Cai J
    Expert Opin Ther Pat; 2013 Aug; 23(8):1075-81. PubMed ID: 23806121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of antibiotic-induced endotoxin release.
    Prins JM; van Deventer SJ; Kuijper EJ; Speelman P
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1211-8. PubMed ID: 8092816
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibiotic induced endotoxin release and clinical sepsis: a review.
    Holzheimer RG
    J Chemother; 2001 Nov; 13 Spec No 1(1):159-72. PubMed ID: 11936361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic-mediated release of endotoxin and the pathogenesis of gram-negative sepsis.
    Morrison DC
    Prog Clin Biol Res; 1998; 397():199-207. PubMed ID: 9575560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endotoxin in endodontic infections: a review.
    Mohammadi Z
    J Calif Dent Assoc; 2011 Mar; 39(3):152-5, 158-61. PubMed ID: 21563594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria.
    Teng CB; Koh PT; Lye DC; Ang BS
    Int J Antimicrob Agents; 2008 Jan; 31(1):80-2. PubMed ID: 17920246
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergence of polymyxin resistance in Gram-negative bacteria.
    Olaitan AO; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):581-582. PubMed ID: 27939183
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical implications of antibiotic-induced endotoxin release in septic shock.
    Lepper PM; Held TK; Schneider EM; Bölke E; Gerlach H; Trautmann M
    Intensive Care Med; 2002 Jul; 28(7):824-33. PubMed ID: 12122518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.
    Corbett D; Wise A; Langley T; Skinner K; Trimby E; Birchall S; Dorali A; Sandiford S; Williams J; Warn P; Vaara M; Lister T
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on endotoxin neutralization strategies in Gram-negative bacterial infections.
    Brandenburg K; Schromm AB; Weindl G; Heinbockel L; Correa W; Mauss K; Martinez de Tejada G; Garidel P
    Expert Rev Anti Infect Ther; 2021 Apr; 19(4):495-517. PubMed ID: 33210958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
    Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
    Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
    Gales AC; Jones RN; Sader HS
    J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.